"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approved nivolumab and ipilimumab (Opdivo and Yervoy) in combination for treatment of renal cell carcinoma

FDA Approved nivolumab and ipilimumab (Opdivo and Yervoy) in combination for treatment of renal cell carcinoma

29 Jun 2018 8:16 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved nivolumab and ipilimumab (Opdivo and Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software